Core Viewpoint - BeiGene's subcutaneous formulation of Tislelizumab has received implied approval from the National Medical Products Administration for clinical trial supplementation, aimed at treating malignant tumors, marking a significant advancement in drug formulation that is expected to enhance patient compliance and market potential [1] Stock Performance - As of February 13, 2026, BeiGene's A-shares (688235) were priced at 279.62 CNY, with a 5-day cumulative increase of 2.61%; Hong Kong shares (06160) were at 208.60 HKD, up 1.66% over the same period; while U.S. shares (ONC.OQ) were at 346.07 USD, down 2.22% [2] - On February 13, 2026, A-share net outflow of main funds was 8.49 million CNY, with a trading volume of 316 million CNY, indicating short-term profit-taking pressure influenced by market sentiment and company events [2] Financial Report Analysis - BeiGene plans to release its financial results for Q4 and the full year of 2025 on February 26, 2026; preliminary data shows a revenue of 27.595 billion CNY for the first nine months of 2025, a year-on-year increase of 44.21%, and a net profit attributable to shareholders of 1.139 billion CNY, up 130.88% year-on-year [3] - The high growth in performance is primarily driven by the sales expansion of core products like Tislelizumab, with investors advised to focus on annual profitability and globalization progress [3] Institutional Perspectives - In the past 90 days, 9 institutions have rated BeiGene, with 8 giving a buy rating and 1 an outperform rating, setting a target average price of 320.0 CNY [4] - Analysts indicate that the company's fundamentals are robust, with strong globalization progress and profitability, although financial risks and market competition should be monitored [4]

Core Insights - Recent developments for BeiGene include the approval of a supplemental application for the subcutaneous formulation of Tislelizumab for malignant tumor treatment, which is expected to enhance patient compliance and market potential [1] - The company plans to release its financial results for Q4 and the full year of 2025 on February 26, 2026, which will be followed by a board meeting and a conference call for investors [1] Stock Performance - BeiGene's stock has shown volatility recently, with A-shares closing at 279.62 CNY, down 1.09% on February 13, 2026, but up 2.61% over the past five days; Hong Kong shares closed at 208.60 HKD, down 0.48%, with a 1.66% increase over five days; and US shares at 350.12 USD, up 1.07% on the same day but down 1.07% over five days [2] - On February 12, 2026, A-share main funds experienced a net outflow of 18.68 million CNY, with a trading volume of 311 million CNY, indicating some profit-taking pressure amid market sentiment [2] Financial Analysis - Preliminary data shows that for the first nine months of 2025, BeiGene reported revenue of 27.595 billion CNY, a year-on-year increase of 44.21%, and a net profit attributable to shareholders of 1.139 billion CNY, up 130.88% [3] - The significant growth in performance is primarily driven by the sales expansion of core products like Tislelizumab, and investors should pay attention to the company's profitability and globalization progress in the upcoming financial report [3]